Andy Slavitt  
Acting Administrator for the Centers for Medicare & Medical Services (CMS)  

April 22nd, 2016  

Dear Mr. Slavitt,  

Biolyse Pharma is a Canadian company that specializes in the manufacturing as well as the development of sterile oncology drugs.  

We are presently writing to express our willingness to supply a generic version of enzalutamide to prostate cancer patients in the United States and in the developing world.  

Presently enzalutamide is sold under the name Xtandi by Astella Pharmaceuticals. It is our understanding, that in 2014, prostate cancer patients receiving reimbursement for their medication were paying an excess of $250 dollars for their daily regime of four tablets of 40mg of enzalutamide. Astella is presently selling in Canada and in other jurisdictions Xtandi for approximately 30% of what it is presently charging in the United States. Biolyse Pharma would be able to supply enzalutamide for approximately $3.00 USD per tablet.  

Medicare has a royalty free right in all three patents in the FDA orange book for enzalutamide. We believe we can have generic versions approved by the FDA in less than three years if CMS is willing to allow Biolyse Pharma to supply the drug using the U.S federal government’s worldwide royalty free license.  

Sincerely,  

Brigitte Kiecken  
President